These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36755262)

  • 1. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
    Wang T; Du G; Niu M; Liu R
    BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
    Xu G; Zhou L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 49(4):628-636. PubMed ID: 39019792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
    Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
    Fang L; Ding G; Wang M; Ye Y; Yan X; Ding P; Wang J; Zhang Y
    Medicine (Baltimore); 2022 Aug; 101(34):e30255. PubMed ID: 36042596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D; Xu X; Wen J; Zhang C; Fan M
    Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
    Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
    Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L; Hou F; Liu Y; Li W; Zhang H
    J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H; Hara M; Iwakami SI; Takahashi K
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
    Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
    J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
    Tao H; Liu Z; Mu J; Gai F; Huang Z; Shi L
    Diagn Pathol; 2022 Feb; 17(1):27. PubMed ID: 35144623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.